2004 Consulting Leads 
European Pharmaceutical Review
JUNE 24, 2022
Following initial consultations in 2021, we expect the publication of the proposal for changes to the EU’s pharmaceutical legislation and potential adoption by the European Commission (EC) by December 2022. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2004. OHE Consulting Report [Internet].
European Pharmaceutical Review
AUGUST 23, 2022
It is also clear that this aspect will inevitably lead to discussions, but the principles on which the composition and activities of the Coordinators’ Group have been established open up a new frontier of political and scientific co-ordination within the EU Member States. effectiveness and therapeutic efficacy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
SEPTEMBER 5, 2023
EMA indicates that, “… the less-than lifetime (LTL) concept or the use of interim limits (≤178 ng/day) may be considered by the lead authority and national competent authorities (NCAs) on a temporary basis in order to inform market actions and at the same time ensure availability of medicines”. Org Process Res Dev. 2023; 10.1021.acs.oprd.3c00008.
pharmaphorum
AUGUST 4, 2022
For instance, in pharmaceutical manufacturing, mistakes in training can lead to contamination or waste, which can cause businesses unnecessary headaches. Lynne Byers, global managing director, Pharmaceuticals and Dietary Supplements Consulting, NSF. About the Author. She joined NSF in 2017. appeared first on.
European Pharmaceutical Review
DECEMBER 20, 2023
Stakeholder reaction to original EC proposals suggests that changes are considered more favourable for generic/biosimilar manufacturers, given reduced RDP periods could lead to earlier generic/biosimilar entry for both non-orphan and orphan drugs ( see Figure 2 ). By contrast, orphan drugs could become less profitable, more risky investments.
PM360
SEPTEMBER 28, 2022
At Roche at the time, his job was to lead a task force which was given the objective of planning a strategy to preserve and protect the companies billion-dollar originator biologics franchises as well as build a plan which would counter the introduction and use of biosimilars. Now, as the President of Accord BioPharma , the U.S.
PM360
APRIL 7, 2023
Introducing CiTRUS Health Group CiTRUS Health Group has launched as a robust, boutique strategic consulting business that allows clients to clearly articulate the scientific, clinical, and real-world evidence to establish a strong value proposition and ultimately successful commercialization.
Expert insights. Personalized for you.
105 
Let's personalize your content